O
BIOA

OrbiMed’s BioAge Labs BIOA Stock Holding History

OrbiMed’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Buy
752,153
+40,342
+6% +$729K 0.34% 66
2026
Q1 		$12.4M Sell
711,811
-79,090
-10% -$1.52M 0.25% 74
2025
Q4 		$10.5M Hold
790,901
– – 0.21% 79
2025
Q3 		$4.65M Sell
790,901
-131,058
-14% -$614K 0.11% 86
2025
Q2 		$3.81M Hold
921,959
– – 0.1% 83
2025
Q1 		$3.47M Hold
921,959
– – 0.08% 86
2024
Q4 		$5.34M Sell
921,959
-501,511
-35% -$8.65M 0.11% 85
2024
Q3 		$29.6M Buy
+1,423,470
New +$28.5M 0.54% 50

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

OrbiMed's BIOA Position: Q2 2026 in Review

OrbiMed increased its BioAge Labs (BIOA) stake by 5.7% in Q2 2026, buying an estimated $729K and bringing the position to 752,153 shares worth $18.4M. The position accounts for 0.34% of the portfolio, ranked #66.

OrbiMed first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. The position peaked at $29.6M in Q3 2024. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • OrbiMed held 752,153 shares of BioAge Labs worth $18.4M as of Q2 2026.
  • OrbiMed bought 40,342 BioAge Labs shares in Q2 2026, an estimated $729K.
  • BioAge Labs made up 0.34% of OrbiMed's portfolio in Q2 2026, its #66 holding.
  • OrbiMed first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • OrbiMed's BioAge Labs position peaked at $29.6M in Q3 2024.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.